Covalent Bruton tyrosine kinase inhibitors (BTKis) have improved CLL management, but discontinuation due to adverse events ...

As therapy for chronic lymphocytic leukemia (CLL) continues to evolve, 2025 brought research, regulatory news, and expert ...

Join Dr Krish Patel and discover groundbreaking updates in lymphoma and CLL treatments, including innovative therapies and ...

Here are the top 5 articles detailing the advancements in hematologic oncology from 2025. BTK inhibitors have revolutionized treatment for hematologic malignancies, butacquired BTK mutations often ...

In a head-to-head trial, Lilly’s drug was as effective as Imbruvica at inducing responses and displayed certain safety advantages that could make it a preferred treatment in early lines of care.

Healio spoke with Matthew S. Davids, MD, about a recent study comparing continuous treatment with a Bruton tyrosine kinase inhibitor with time-limited venetoclax-based therapy for chronic lymphocytic ...

"Second Winds" refers to how diagnosis and treatment of CLL can lead to "fulfilling lives," says Abbvie's Matt Skryja.

Developments in chronic lymphocytic leukemia (CLL) this year included the first CAR T-cell therapy approval for the chronic blood cancer, potential treatments for Richter transformation, and ...

Chronic lymphocytic leukemia (CLL) is a type of blood cancer that affects white blood cells called lymphocytes. There are many types of leukemia, and CLL is a common type in adults. This type of ...